Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study
BM Costa, C Caeiro, I Guimarães… - Oncology …, 2010 - spandidos-publications.com
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. The
identification of novel molecular prognostic markers of GBM has recently been an area of
great interest in neuro-oncology. The methylation status of the MGMT gene promoter is
currently a promising molecular prognostic marker, but some controversial data have
precluded its clinical use. We analyzed MGMT methylation by methylation-specific PCR in
90 GBM patients from four Portuguese hospitals, uniformly treated with radiotherapy …
identification of novel molecular prognostic markers of GBM has recently been an area of
great interest in neuro-oncology. The methylation status of the MGMT gene promoter is
currently a promising molecular prognostic marker, but some controversial data have
precluded its clinical use. We analyzed MGMT methylation by methylation-specific PCR in
90 GBM patients from four Portuguese hospitals, uniformly treated with radiotherapy …
Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation
K Wang, YY Wang, J Ma, JF Wang, SW Li… - Asian Pacific Journal …, 2015 - koreascience.kr
Several molecular markers have been proposed as predictors of outcome in patients with
glioblastomas. We investigated the prognostic significance of $ O^ 6$-methylguanine-DNA
methyltransferase (MGMT) promoter methylation and TP53 mutation status dependent on
isocitrate dehydrogenase 1 (IDH1) mutation in glioblastoma patients. A cohort of 78 patients
with histologically confirmed glioblastomas treated with radiation therapy and chemotherapy
were reviewed retrospectively. We evaluated the prognostic value of MGMT promoter …
glioblastomas. We investigated the prognostic significance of $ O^ 6$-methylguanine-DNA
methyltransferase (MGMT) promoter methylation and TP53 mutation status dependent on
isocitrate dehydrogenase 1 (IDH1) mutation in glioblastoma patients. A cohort of 78 patients
with histologically confirmed glioblastomas treated with radiation therapy and chemotherapy
were reviewed retrospectively. We evaluated the prognostic value of MGMT promoter …
以上显示的是最相近的搜索结果。 查看全部搜索结果